Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Thibaut Sanglier"'
Autor:
Thibaut Sanglier, Jinjoo Shim, Neil Lamarre, Claudia Peña-Murillo, Vincent Antao, Filippo Montemurro
Publikováno v:
Breast, Vol 69, Iss , Pp 441-450 (2023)
Background: Trastuzumab emtansine (T-DM1) has demonstrated improvements in survival and neurological symptoms in patients with breast cancer with brain metastases (BCBM). This real-world study investigated the effectiveness of T-DM1 versus lapatinib
Externí odkaz:
https://doaj.org/article/dc6441ba5eec4f8093e6c924597ba37f
Publikováno v:
Breast, Vol 66, Iss , Pp 262-271 (2022)
Upon its establishment for the treatment of metastatic breast cancer (mBC), continuing trastuzumab beyond disease progression was an important paradigm shift that became the recommendation by major guidelines. However, data supporting continuation of
Externí odkaz:
https://doaj.org/article/29430a3d39e94a09934c3b340cabaf0c
Autor:
Thibaut Sanglier, Alessandra Fabi, Carlos Flores, Evelyn M. Flahavan, Claudia Pena-Murillo, Anne-Marie Meyer, Filippo Montemurro
Publikováno v:
Cancers, Vol 14, Iss 10, p 2468 (2022)
Real-world studies have suggested decreased trastuzumab emtansine (T-DM1) effectiveness in patients with metastatic breast cancer (mBC) who received prior trastuzumab plus pertuzumab (H + P). However, these studies may have been biased toward pertuzu
Externí odkaz:
https://doaj.org/article/9201c44335444a39ad4c3fc86e5a7331
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Letizia Polito, Jinjoo Shim, Sara A. Hurvitz, Chau T. Dang, Adam Knott, Yolande Du Toit, Eleonora Restuccia, Thibaut Sanglier, Sandra M. Swain
Publikováno v:
JCO Oncology Practice.
PURPOSE On the basis of the results from CLEOPATRA, pertuzumab plus trastuzumab and chemotherapy is the first-line standard of care for human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC). However, discrepancies
Autor:
Preet K. Dhillon, Peter Lambert, Thibaut Sanglier, Adam Knott, Eleonora Restuccia, Sanne L. de Haas, Chiara Lambertini
Publikováno v:
Cancer Research. 82:P3-13
Introduction: Pts with HER2-positive metastatic BC (mBC) often develop CNS mets, which is associated with poor prognosis and negative impact on quality of life. Resistance to anti-HER2 treatment can lead to disease progression; furthermore, many ther
Publikováno v:
Cancer Research. 82:P2-13
Background: Continuing trastuzumab beyond disease progression was one of the most important paradigm changes in Oncology and is recommended by all guidelines. The reason behind it is that metastatic breast cancer (MBC) progresses much faster when the
Autor:
Marija Balic, Luis Costa, Joseline Ojaimi, Cristina Marinela Oprean, José L. Passos Coelho, Isabel Pazos, Fabio Puglisi, Thibaut Sanglier, Giuseppa Scandurra, Michael Schenker, Laurentia A. Wahyudi, Georgi Zhbantov, Constanta Timcheva
Publikováno v:
Cancer Research. 83:P3-02
BACKGROUND: Metastatic breast cancer (MBC) is incurable, with the primary goal of treatment being to extend survival while preserving quality of life. Treatment options available to patients (pts) with human epidermal growth factor receptor-2 positiv
Autor:
Thibaut Sanglier, D. Tesarowski, Patricia Luhn, Eleonora Restuccia, Anita Fung, Carlos Flores, Preet K. Dhillon, Devin Incerti, Vincent Antao
Publikováno v:
Cancer Research. 81:PS10-20
OBJECTIVES Over the last decade, new treatment options have transformed the standard of care for patients (pts) with HER2-positive EBC and the treatment landscape continues to evolve. The primary objectives of our study were (1) to describe and compa
Publikováno v:
Cancer Research. 80:P1-18
Background: Clinical practice guidelines recommend the combination of pertuzumab (PERJETA®), trastuzumab (Herceptin®) (PH) and a taxane for first-line treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer (HER2+ mB